Related Experiment Videos
Immunotherapeutic perspective for bispecific antibodies
A B van Spriel1, H H van Ojik, J G van De Winkel
1Immunotherapy Laboratory, Dept of Immunology and Medarex Europe, University Medical Center Utrecht, Room KC02.085.2, Lundlaan 6, 3584 EA Utrecht, The Netherlands.
Immunology Today
|August 1, 2000
Summary
Bispecific antibodies (BsAb), combining two binding sites, enhance disease treatment selectivity and efficacy. Recent findings highlight BsAb
Area of Science:
- Immunology
- Biotechnology
- Therapeutics
Background:
- Bispecific antibodies (BsAb) offer dual-binding capabilities for improved therapeutic selectivity and efficacy.
- Both 'anti-trigger' and 'anti-target' modalities are crucial for BsAb therapeutic success.
Purpose of the Study:
- To review recent advancements in bispecific antibody (BsAb) research.
- To discuss the translation of BsAb concepts into clinical therapies.
Main Methods:
- Review of recent scientific literature and studies on bispecific antibodies.
- Analysis of the mechanisms underlying BsAb efficacy, including cytotoxicity and 'vaccine effects'.
Main Results:
- Bispecific antibodies demonstrate significant potential in improving treatment outcomes.
- BsAb exhibit dual functions: inducing effective cytotoxicity and 'vaccine effects' in vivo.
Conclusions:
- Recent findings have spurred renewed efforts in developing bispecific antibody therapies.
- The therapeutic translation of bispecific antibody concepts is a key focus for future research.